ArriVent BioPharma (AVBP) Competitors $21.62 -0.25 (-1.14%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$21.77 +0.15 (+0.69%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP vs. HCM, CRNX, ALVO, AMRX, OGN, CPRX, BHC, MIRM, XENE, and ARWRShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include HUTCHMED (HCM), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Bausch Health Cos (BHC), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Its Competitors HUTCHMED Crinetics Pharmaceuticals Alvotech Amneal Pharmaceuticals Organon & Co. Catalyst Pharmaceuticals Bausch Health Cos Mirum Pharmaceuticals Xenon Pharmaceuticals Arrowhead Pharmaceuticals ArriVent BioPharma (NASDAQ:AVBP) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Do analysts recommend AVBP or HCM? ArriVent BioPharma currently has a consensus price target of $39.29, suggesting a potential upside of 81.71%. HUTCHMED has a consensus price target of $19.00, suggesting a potential upside of 14.73%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, AVBP or HCM? ArriVent BioPharma has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Which has preferable earnings & valuation, AVBP or HCM? HUTCHMED has higher revenue and earnings than ArriVent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$80.49M-$3.77-5.73HUTCHMED$630.20M4.58$37.73MN/AN/A Do institutionals & insiders hold more shares of AVBP or HCM? 9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 18.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor AVBP or HCM? In the previous week, ArriVent BioPharma had 1 more articles in the media than HUTCHMED. MarketBeat recorded 3 mentions for ArriVent BioPharma and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.47 beat ArriVent BioPharma's score of 1.29 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AVBP or HCM more profitable? HUTCHMED's return on equity of 0.00% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -49.21% -46.61% HUTCHMED N/A N/A N/A SummaryArriVent BioPharma beats HUTCHMED on 8 of the 13 factors compared between the two stocks. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$748.23M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-5.7320.2228.5419.58Price / SalesN/A299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book2.837.568.145.54Net Income-$80.49M-$55.11M$3.24B$257.73M7 Day Performance1.31%3.81%0.18%-0.08%1 Month Performance-14.95%11.60%5.96%8.09%1 Year Performance9.08%-2.11%26.24%13.02% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma2.2688 of 5 stars$21.62-1.1%$39.29+81.7%+10.1%$748.23MN/A-5.7340HCMHUTCHMED1.6148 of 5 stars$15.92+3.2%$19.00+19.3%-11.4%$2.78B$630.20M0.001,811Gap DownCRNXCrinetics Pharmaceuticals3.4288 of 5 stars$29.42+1.2%$71.75+143.9%-41.2%$2.75B$1.04M-7.69210ALVOAlvotech3.4038 of 5 stars$8.92-1.1%$18.00+101.8%-30.5%$2.69B$491.98M24.121,032AMRXAmneal Pharmaceuticals2.568 of 5 stars$8.35-0.8%$11.60+39.0%+12.1%$2.63B$2.79B-209.578,100OGNOrganon & Co.4.8159 of 5 stars$10.05+3.3%$18.00+79.2%-53.9%$2.62B$6.40B3.494,000Trending NewsCPRXCatalyst Pharmaceuticals4.9219 of 5 stars$21.00+0.2%$32.83+56.4%+25.1%$2.56B$491.73M13.3780BHCBausch Health Cos3.7766 of 5 stars$6.84-0.5%$7.42+8.5%-12.4%$2.53B$9.63B-62.1420,700MIRMMirum Pharmaceuticals3.8748 of 5 stars$50.11-0.7%$65.50+30.7%+31.7%$2.49B$336.89M-31.16140XENEXenon Pharmaceuticals3.5691 of 5 stars$31.74-0.3%$54.82+72.7%-24.9%$2.44B$9.43M-9.84210Positive NewsARWRArrowhead Pharmaceuticals3.5528 of 5 stars$17.53+4.1%$43.71+149.3%-38.9%$2.43B$545.21M-12.56400News Coverage Related Companies and Tools Related Companies HUTCHMED Competitors Crinetics Pharmaceuticals Competitors Alvotech Competitors Amneal Pharmaceuticals Competitors Organon & Co. Competitors Catalyst Pharmaceuticals Competitors Bausch Health Cos Competitors Mirum Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVBP) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVBP Stock Alerts